** Nurix Therapeutics Inc's NRIX.O shares down 5.3% at $16.30 premarket after overnight follow-on priced
** Biopharma firm late Thurs announced ~11.7 mln shares, including 1.5 mln pre-funded warrants, at $15 for $175 mln gross raise
** Offering size boosted from $125 mln, priced at 12.8% discount to last sale
** Co plans to use offering proceeds to fund clinical development of drug candidates, fund R&D
** NRIX shares on Tues closed up 27% at $17.48 after co announced extension of collaboration with Sanofi SASY.PA and reported first findings of clinical responses in the brain for NX-5948, its treatment for B cell malignancies
** Nurix earlier this month announced collaboration extension with Gilead Sciences GILD.O. In Q4 2023, co entered collaboration with Pfizer PFE.N
** With ~49.2 mln shares outstanding, Nurix has ~$846 mln market cap
** Shares up 67% YTD through Thurs
** JP Morgan, Piper Sandler and Stifel jt bookrunners for stock offering
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-646-279-6380))